PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEBSITE. BY ACCESSING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THIS SITE.
Soligenix is working hard to ensure that the information provided on this site is accurate and up-to-date but due to the risk that the information may be compromised by software or procedural errors, Soligenix does not guarantee the accuracy or completeness of the information provided on this site. Soligenix reserves the right to make changes to the content of this site from time to time without notice or obligation.
Permission to Browse Site and Limited Permission to Make Copies:
You may browse this site for information and may print copies of its contents for your own use. Written permission is required, however, if you want to incorporate the contents into you own site or written materials, create “derivative works” or revise the site contents. In addition, you may not “mirror” the contents of this site without Soligenix’s permission. To seek permission, please e-mail firstname.lastname@example.org.
Although it may be easy to copy in cyberspace, this does not mean it is legal to do so.
PhotoDisc, The Image Works, meister.NET and Soligenix, Inc.
orBec® is a registered trademark and Oraprine™, RiVax™, LPM™, LPE™, PLP™ and MicroVax™ are trademarks of Soligenix, Inc. Registrations exist in the United States and various countries throughout the world. Biothrax™ is a trademark of the Bioport Corporation. Imuran® is a registered trademark of Glaxo Wellcome. Taxol® is a registered trademark of Bristol-Myers Squibb. Lupron® is a registered trademark of TAP Pharmaceuticals, Inc. For more complete information regarding the status of a particular trademark in a particular country, please contact Soligenix.
Copyright in the pages and in the screens displaying the pages, and in the information and material therein and in their arrangement, is owned by the Soligenix, Inc. unless otherwise indicated. Some contents of this site may be registered with the Federal Copyright Office. Please familiarize yourself with US and International Copyright laws before using any material.
Links to Third Party Websites:
Please understand that when you access another website through this one, Soligenix can accept no responsibility for your experience with the site. In addition, a link to a non-Soligenix site does not mean that Soligenix endorses or recommends that site or its contents.
The information provided in the Investor Relations section of this site is provided through a hypertext link to a third party website. (See above for important information about links to third party websites.) Under no circumstances will Soligenix be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the inherent risks of the stock market.
Communications with Soligenix:
Any communications or material transmitted to Soligenix will be treated as non-confidential and non-proprietary unless otherwise noted. Soligenix shall be free to reproduce, use, disclose and distribute these communications to third parties without restriction. Soligenix shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.
No Warranties; Limitations of Liability:
Soligenix assumes no responsibility for errors or omissions on this website. ACCESS TO THIS SITE IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. Soligenix shall not be liable for any special, indirect, incidental, or consequential damages, including without limitation lost revenues or lost profits, which may result for the use of this site.
Anyone using this website acknowledges that Soligenix may monitor the website contents as needed to comply with the law, to protect Soligenix and visitors to this website and to ensure that the website is being operated properly.
Policy on Financial Conflicts of Interest (FCOI) in Public Health Service (PHS) Funded Research
This Policy implements Financial Conflicts of Interest (FCOI) disclosure requirements found in 42 CFR Part 50 and 45 CFR Part 94 which are applicable to Research funded by the U.S. Public Health Service. This regulation does not apply to Phase I Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) program applications or awards. As a condition for receiving PHS funding, these regulations require Soligenix to maintain an appropriate written policy on financial conflict of interest disclosure. These requirements are applicable to all Research projects for which Soligenix submits a proposal to or receives Research funding from PHS, except for Phase I SBIR or STTR Research projects, as noted above. Each Investigator, as defined in the Policy, that is planning to participate in, or is participating in such Research, must follow this process and complete the required training. Subcontractors/consultants who perform services within the definition of an Investigator must maintain a policy that complies with the aforementioned regulatory requirements or comply with this Policy. Questions regarding this Policy should be directed to Soligenix’s Institutional Official.
Consistent with these requirements, Soligenix’s Policy, Soligenix FCOI Disclosure Form (pdf) and required FCOI Disclosures are available. The FCOI Disclosure information is current as of October 12, 2012 and is subject to updates at least annually as well as within 60 days of Soligenix’s identification of a new Financial Conflict of Interest.
This website may contain forward-looking statements that reflect Soligenix, Inc.’s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “intends,” “potential,” or similar expressions, are forward-looking statements.
These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix’s reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
About Soligenix, Inc.
Located in Princeton, New Jersey, Soligenix, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.
Through our BioDefense Division, the company is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Specifically, Soligenix is developing stable bioengineered vaccines designed to protect against the deadly effects of ricin toxin, botulinum toxin and anthrax, all of which are considered serious bioterrorism threats.